Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
Wallowing in self-pity is tempting in the wake of an Alzheimer's diagnosis, but it's crucial to keep moving forward, says columnist Ray Burow.| Alzheimer's News Today
A breast cancer diagnosis is particularly problematic — yet possible — for women caregivers, columnist Ray Burow writes.| Alzheimer's News Today
Columnist Ray Burow remembers her recently passed mother-in-law, who remained loving and loved during her short-term memory loss.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.| Alzheimer's News Today
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ADVANCE-2 didn't.| Alzheimer's News Today
Experts in Alzheimer’s and dementia care explain the challenges of getting an early and accurate diagnosis and what can be done to solve it.| Alzheimer's News Today
A rare APOE gene mutation may protect against Alzheimer's by stopping the spread of toxic tau protein clumps in the brain, a study found.| Alzheimer's News Today
Patricia Inacio is a science writer for Alzheimer's News Today with a PhD in cell biology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Steve Bryson is a science writer for Alzheimer's News Today with a PhD in biochemistry. He covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Amylyx Pharmaceuticals' oral therapy candidate AMX0035 improves levels of several biomarkers associated with Alzheimer's, per a new analysis.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today
Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.| Alzheimer's News Today
Alpha Cognition’s ALPHA-1062 for Alzheimer’s showed efficacy in a trial as a bioequivalent substitute for the approved therapy Razadyne.| Alzheimer's News Today
Alpha Cognition’s oral tablet ALPHA-1062 may be a bioequivalent to galantamine hydrobromide – sold as Razadyne – for Alzheimer’s disease.| Alzheimer's News Today
Being a sole caregiver for a loved one with Alzheimer's is hard work, says columnist Ray Burow, but help and resources are available.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Taking on caregiving for a loved one with Alzheimer's can seem impossible, says columnist Ray Burow, but only until it's done.| Alzheimer's News Today
There is great value in the relationship between grandparents and grandchildren, columnist Ray Burow says, even if Alzheimer's is involved.| Alzheimer's News Today
Margarida Maia is a science writer for Alzheimer's News Today with a PhD in biomedical sciences. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Treatment with Lomecel-B in early Alzheimer's patients led to improvements in cognitive tests relative to a placebo in a clinical trial.| Alzheimer's News Today
After her father passed away, columnist Ray Burow had to help her mother, who had Alzheimer's, process her emotions and grief.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Columnist Ray Burow, reflecting on caregiving for her late mother, ponders if it's sometimes OK to lie to a person with Alzheimer's disease.| Alzheimer's News Today
The use of Montelukast oral film was shown to improve cognition in patients with mild to moderate Alzheimer's in a Phase 2 clinical trial.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
With the high temperatures expected this summer, columnist Ray Burow recalls tips she used to help loved ones with dementia handle the heat.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
Columnist Ray Burow can attest to the challenges that sandwich generation caregivers face, but says her children learned valuable lessons.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today
Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today